Recommended Protocol for Intraperitoneal Injection of Anti-Mouse PD-1 Antibody

Executive Summary

This standardized protocol provides evidence-based guidance for the intraperitoneal (IP) administration of InvivoPro Anti-Mouse PD-1 (CD279) Antibody (Clone RMP1-14, Cat. No. IV0100) in preclinical mouse models. Developed from aggregated independent research data, this document includes optimized dosage ranges, injection parameters, operational best practices, safety monitoring guidelines, and model-specific adjustments to ensure robust, reproducible results in tumor immunology and immune checkpoint blockade studies.

Introduction

Programmed Cell Death Protein 1 (PD-1, CD279), first characterized by Honjo and colleagues in 1992, is a key member of the immunoglobulin superfamily that plays a central role in regulating immune homeostasis and T cell activation. PD-1 exerts its immunomodulatory effects by binding to its ligands PD-L1 and PD-L2, delivering an inhibitory signal that sets the activation threshold of T cells to prevent aberrant autoimmune responses. This critical regulatory function is validated by studies showing that PD-1-deficient mice develop hyperglobulinemia and spontaneous autoimmune pathologies, including glomerulonephritis and arthritis.

In the tumor microenvironment, malignant cells frequently upregulate PD-L1 expression to engage PD-1 on tumor-infiltrating T cells, driving T cell exhaustion and immune escape. Therapeutic blockade of the PD-1/PD-L1 axis with specific antibodies reverses this immunosuppressive state, restores the anti-tumor effector function of T cells, and has become a first-line immunotherapy strategy for a broad range of solid malignancies, including melanoma, non-small cell lung cancer, renal cell carcinoma, and hepatocellular carcinoma.

Clone RMP1-14 is a well-validated, high-specificity rat anti-mouse PD-1 monoclonal antibody widely used for in vivo blockade of the PD-1/PD-L1 signaling pathway in preclinical mouse studies. This protocol outlines standardized IP administration procedures for this antibody to support consistent, high-quality preclinical research.

Product Specification

Recommended Intraperitoneal (IP) Injection Protocol

All parameters below are reference recommendations derived from published peer-reviewed studies. Optimal dosing and administration must be optimized for individual experimental conditions, including mouse strain, disease model, intervention duration, target tissue characteristics, and antigen expression levels. We strongly recommend validating parameters in pilot dose-gradient and frequency-finding studies prior to full-scale experiments.

1. Recommended Dosage Ranges

2. Recommended Injection Volume & Solvent

3. Dosing Frequency

Critical Operational Guidelines & Optimization Recommendations

1. Solvent Selection & Antibody Stability Control

1. Buffer Requirements: Prioritize sterile, pH 7.2 PBS buffer to minimize antibody aggregation and preserve bioactivity.
2. Prohibited Solvents: Do not use solvents containing endotoxins; all materials and solutions must be sterile for in vivo studies.
3. Optimal Formulation Concentration: 1–2 μg/μL (e.g., 200 μg in 100–200 μL) to balance physiological osmolarity and in vivo distribution efficiency.

2. Safe Injection Volume Thresholds

1. Absolute Maximum Single Dose Volume: ≤10 mL/kg body weight (equivalent to 200 μL for a 20 g mouse)
2. Conservative Recommended Volume: ≤5 mL/kg body weight (equivalent to 100 μL for a 20 g mouse) to avoid acute increases in intra-abdominal pressure and visceral injury.

3. Validated Combination Treatment Strategies

Safety Monitoring & Control Group Setup

1. Immune-Related Adverse Events (irAEs) Monitoring

Routine monitoring is required to detect and mitigate irAEs, the most common of which include:

1. Body weight loss >20% of baseline
2. Intestinal microbiota dysregulation and associated gastrointestinal adverse events

Additional monitoring of behavior, cardiac biomarkers, and organ function is recommended for combination therapy studies. If body weight decreases by >15% from baseline within 48 hours of the first dose, reduce the subsequent dose to 150 μg per injection.

2. Mandatory Control Groups

Special Considerations for Specific Experimental Models

1. Adjustments for Mouse Body Weight Variations

1. Young Mice (<15 g body weight): Calculate dose using the 10 mg/kg body weight-based regimen (e.g., 100 μg for a 10 g mouse)
2. Obese Mouse Models: Calculate dose based on lean body mass (LBM) rather than total body weight to avoid overdosing and excessive toxicity.

2. Tumor Type-Specific Adjustments

1. Hepatocellular Carcinoma with Concurrent Liver Cirrhosis: Reduce dose to 150 μg per injection to minimize the risk of exacerbating liver function impairment.
2. Pancreatic Cancer (Low Immune Infiltration Phenotype): Combine with local adjuvant therapy (e.g., intratumoral oxygen microcapsules) to enhance antibody penetration into the tumor microenvironment and improve treatment efficacy.

Quick Reference Summary Table

Critical Operational Tip

For 22–25 g mice: Prepare 200 μg of RMP1-14 antibody in 200 μL sterile PBS. Insert the needle into the left lower abdomen at a 45° angle, with an injection speed ≤50 μL/s to prevent visceral injury. Monitor body weight 48 hours after the first dose; reduce the dose to 150 μg per injection if body weight drops by >15% from baseline.

About InvivoCrown

InvivoCrown, founded in 2021 at Cambridge Science Park, UK, is a specialist provider of high-purity, cost-effective in vivo-grade antibodies for global immunology and oncology research. Backed by Cambridge University immunology experts, our rigorously validated antibodies cover both classic and novel therapeutic targets.

Keywords

Anti-Mouse PD-1 Antibody, RMP1-14 Clone, In Vivo IP Injection Protocol, Tumor Immunotherapy Research, Immune Checkpoint Inhibition, IV0100 Antibody, Mouse Preclinical Models, PD-1/PD-L1 Pathway Blockade